Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer : vimarsana.com

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Related Keywords

Rena Callahan , William Gradishar , Mabel Mardones , Gregory Vidal , Peer Exchange , Oral Serd , Mbc , Metastatic Breast Cancer , Serd , Therapeutic Advances , Panel Discussion , Er Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Oncologist , Breast Oncology , Elacestrant , Breast Cancer , Clinical Guidelines , Fda Label , Nccn Guidelines , Esr1 Mutations , Treatment Resistance , Oral Therapy , Disease Progression , Patient Profiles , Precision Medicine , Metastatic Cancer , Treatment Sequencing , Liquid Biopsy Tissue Testing , Precision Oncology , Therapeutic Strategies , Treatment Failure Criteria , Patient Selection , Dosage Modifications , Toxicity Comparison , Breast Cancer Treatment ,